In recent years, we have seen the widespread devastations and serious health complications manifested by COVID-19 globally. Although we have effectively controlled the pandemic, uncertainties persist regarding its potential long-term effects, including prolonged neurological issues. To gain comprehensive insights, we conducted a meta-analysis of mass spectrometry-based proteomics data retrieved from different studies with a total of 538 COVID-19 patients and 523 healthy controls. The meta-analysis revealed that top-enriched pathways were associated with neurological disorders, including Alzheimer’s (AD) and Parkinson’s disease (PD). Further analysis confirmed a direct correlation in the expression patterns of 24 proteins involved in Alzheimer’s and 23 proteins in Parkinson’s disease with COVID-19. Protein–protein interaction network and cluster analysis identified SNCA as a hub protein, a known biomarker for Parkinson’s disease, in both AD and PD. To the best of our knowledge, this is the first meta-analysis study providing proteomic profiling evidence linking COVID-19 to neurological complications.
CITATION STYLE
Mahin, A., Soman, S. P., Modi, P. K., Raju, R., Keshava Prasad, T. S., & Abhinand, C. S. (2024). Meta-analysis of the serum/plasma proteome identifies significant associations between COVID-19 with Alzheimer’s/Parkinson’s diseases. Journal of NeuroVirology. https://doi.org/10.1007/s13365-023-01191-7
Mendeley helps you to discover research relevant for your work.